SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 784.45-0.4%Nov 26 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Miljenko Zuanic4/17/2015 3:34:18 PM
   of 3559
 
Update on REGN clinical trial for new programs:

1. REGN2176-3 for AMD, P2, 500 pts, 12 W, two dose, v Af clinicaltrials.gov

2. Dupilumab for persistent asthma (broad population), 1638 pts 12/52W P3 clinicaltrials.gov

3. REGN2222 for infant RSV, P3, 24 pts, Australia clinicaltrials.gov

With expected progress on other programs, and UNCERTAINTY with market A-lunch, it is my speculation for significant appreciation in MC for next 12 months.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News